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Liposomes, also known as nontoxic, biodegradable, and non-immunogenic therapeutic
delivery vehicles, have been proposed as a carrier for drugs and antitumor agents in cancer
chemotherapy. Echogenic liposomes (ELIP) have the potential to entrap air or bioactive gas to
enhance acoustic reflectivity in ultrasound and are used as a contrast agent. The innovative part
of this study is based on a novel concept to encapsulate nitric oxide (NO) gas into ELIP, deliver
it to breast cancer cells, and control its release via direct ultrasound exposure. Studies on the
effect of NO in tumor biology have shown that a high levels of NO (> 300 nM) leads to
cytostasis or apoptosis by decreasing the translation of several cell cycle proteins and stimulating
cancer cell death by activating the p53 pathway. The central hypothesis is that NO gas can be
packaged and delivered through a delivery methodology to breast cancer cells to facilitate tumor
regression with minimal systemic toxicity. The primary goal of this thesis is to develop an
echogenic liposomal solution that has the ability to encapsulate NO, to release NO locally upon
ultrasound exposure, and to induce breast cancer cell death. NO-containing echogenic liposomes
(NO-ELIP) were prepared by the freezing-under-pressure method previously developed in our
laboratory. It was necessary to evaluate stability of NO-ELIP and release of NO from NO-ELIP
by measuring echogenicity using intravascular ultrasound images. Breast cancer cell lines,
MDA-MB-231 and MDA-MB-468, were selected to investigate the cytotoxic effects of NO
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liberated from NO-ELIP and their response to NO concentration. Ultrasound-triggered NO
release from NO-ELIP using ultrasound activation was studied. It was demonstrated that NOELIP remained stable for 5 hours in bovine serum albumin. Delivery of NO using NO-ELIP
induced cytotoxicity and programmed cell death of MDA-MB-231 and MDA-MB-468 after 5
hours of incubation. Enhancement of the NO-ELIP effect for therapeutic application was
observed with ultrasound activation. This work demonstrates that NO-ELIP can incorporate and
deliver NO to breast cancer cells providing increased NO stability and ultrasound-controlled NO
release. Improved therapeutic effect with the use of NO-ELIP is expected to be found for breast
cancer treatment.
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CHAPTER Ι
General Introduction

１

1.1. Epidemiology of breast cancer
Breast cancer is the most common type of cancer occurring among women in the United
States (1). Breast cancer also remains principal cause of death among women aged 30-55 years
(2). According to survey from the American Cancer Society, there were an estimated 207,090 of
new breast cancer cases in 2010. About 28% of women are expected to be diagnosed with breast
cancer in their life time in the United States (1).
In 2002, Baum and Schipper reported that the increase incidence of breast cancer is
mainly related to ages, environmental risk factors, and genetic factors (2). Approximately 50 %
of breast cancers occur in women aged 50-64 years and 30 % occur in women over the age of 70
(2). In terms of environmental factors, there is a higher incidence in women from developed
countries (2, 3). However, the incidence rates are rapidly increasing in developing countries. A
family history of breast cancer, as a genetic factor, is also accepted as a risk factor for breast
cancer (2). Women with a first-degree relative with breast cancer have 2-3 fold increase in the
risk of breast cancer (2, 3).
Breast cancer is a heterogeneous disease since there are several prognostic factors and
clinical forms (4). There are numerous factors to influence the incidence of breast cancer and its
origin (5,6). It is important to understand breast microenvironment in order to elucidate the
physiological features and development of breast cancer (6).
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1.2. Anatomy of breast
The breast consists of glandular, fatty and fibrous tissue positioned over the pectoral
muscles of the chest wall (7). As shown in Fig 1.1, the glandular tissues are composed of 15-20
lobes containing numerous lobules known as milk glands (4). Lobules are linked by ductules that
transport milk from lobules to the nipple (7). Lobules and ducts are surrounded by two layers of
fibrous tissue; a superficial layer and thicker deep layer connected by Cooper’s ligaments (2). It
is essential to understand the surrounding tissue of breast because breast cancer is associated
with tissue sites of adenocarcinoma (8). Additionally, tissue microenvironment can profoundly
affect on the incidence of invasive breast cancer (8).
Most malignant breast cancers arise from a group of abnormal cells in ducts and lobules
shown in Fig 1.2 (2). The origins of breast have invaded to surrounding tissues which support
the lobules and ducts of the breast (5). About 90 % of breast cancer consist of invasive ductal
cancer (5). Invasive lobular carcinoma is the second most common type of breast cancer (2).
Lobular carcinoma in situ is not invasive, however, there is rapid increase of abnormal cell
proliferation in the breast lobule (2). When the origin of breast cancer is well understood, breast
cancer treatment would be more effective (2).

３

Figure 1.1 Structure of normal breast (2)
Adapted from Baum, M.
The diagram depicts the anatomy of breast. Breast lobules are linked to ductules to transport
milk to the nipple. Lobules and ducts are surrounded by Cooper’s ligaments which are connected
to fibrous tissue. The intraductal system is erratic and strongly correlated with the incidence of
breast cancer.

Figure 1.2 Types of breast cancer (2)
Adapted from Baum, M.
Invasive breast cancer are generated from lobules and ductules, which invade the surrounding
tissue. Lobular carcinoma in situ stimulates abnormal cell proliferation, yet does not metastasize
to breast tissues around the ducts and lobules.
４

1.3. Conventional breast cancer therapy
1.3.1. Hormone therapy
Breast cancer cells express proteins called estrogen receptor (ER) and progesterone
receptor (PR) (9). ER can modulate breast cancer cell growth in response to one of the sex
hormone, estrogen, and its overexpression leads to faster breast tumor growth (9). Hormone
therapy, known as adjuvant endocrine therapy, is used to treat pre-menopausal women with
hormone receptor (HR)-positive breast cancer and post-menopausal women who have aromatase
inhibitor (10). ER, a transcription factor, is one of the nuclear hormone receptors superfamily
that regulates transcription of target genes (11). When ER binds to estrogen, ER undergoes
receptor dimerization and activation. Ligand-bound ER translocates to the nucleus followed by
full activation of transcription of genes, which can stimulate cancer growth.
Tamoxifen has been commonly used as an anti-estrogen drug for invasive breast cancer
treatment (11, 12). Tamoxifen binds to ER, prevents ER from interacting with estrogen, and
reduces breast cancer cell proliferation (11). Hormone therapy with tamoxifen in patients who
suffer from ductal carcinoma in situ (DCIS) decreases the risk of developing invasive cancer
(10).
Hormonal therapy reduces relapse of breast cancer and extends patient survival by 10
years (9, 13). However, it has been reported that the clinical effect of tamoxifen relies on ER/PR
status (9). ER/PR-positive breast tumor has about 80 % chance to respond to tamoxifen, while
there is 40 % chance in response to tamoxifen with the expression of ER (10). The combination
of hormone therapy such as tamoxifen and goserelin is needed to overcome the limitation of a
single hormone therapy (14).
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1.3.2. Immunotherapy
The prevalence of human epidermal growth factor receptor 2 (Her-2) is expressed in
approximately 25 % of breast tumors (9). Her-2 has potential to be used as a prognostic marker
for the detection of early invasive breast cancer (15). The overexpression of Her-2, a receptor
tyrosine kinase, on the surface of a breast cancer cell membrane induces cell proliferation
through the Ras-Raf-mitogen-activated protein kinase (MEK)/ERK pathway as well as survival
signaling through phosphorylation of Akt followed by the onset of transcription of growthassociated gene (9).
Trastuzumab, anti-Her-2 Mab; Herceptin, is a monoclonal antibody and targeted antiHer-2 oncoprotein and is commonly used to treat patients with invasive breast cancer (16).
Trastuzumab inhibits Her-2 dimerization by binding the extracellular domain of Her-2 and
reducing high proliferation rate (9). In a phase comparison trial, trastuzumab in combination
with chemotherapy has improved overall survival for patients who have Her-2-positive
metastatic breast cancer (17). The addition of trastuzumab to chemotherapy leads to better
results such as a 25.1 more months median survival than standard chemotherapy alone (9, 17).
Adjuvant chemotherapy with trastuzumab has become standard in patients with Her-2-positive
early-staged breast cancer and shown the improvement of response rate and overall survival
(15).

1.3.3. Anti-cancer therapy
Cytotoxic drugs affect the inhibition of malignant cell proliferation and growth (18).
Anthracyclins, one of cytotoxic drugs, is widely used in chemotherapy for early-staged and
advanced breast cancer (19) . However, the cumulative anthracyclines dose induces cardiac
toxicity and myelosuppession that in turn limits medical use (18, 20). Therefore, many studies
６

have focused on preserving cytotoxic drug delivery systems for better drug safety profiles and
therapeutic efficacy (20).
Liposomal doxorubicin has been approved to prolong circulation of drugs and utilized
for the treatment of breast and ovarian cancer (21). Pegylated liposomes, known as sterically
stabilized liposomes, are capable of carrying doxorubicin which is one of the most commonly
used anthracyclines (18). The use of pegylated liposomal doxorubicin (PLD) offers prolonged
circulation time, increase in permeability, and non-toxic circulation (20). PLD enhances
therapeutic index with monotherapy and in combination with chemotherapy (20). It has been
proven that PLD enhances the therapeutic efficacy with less cardiotoxicity compared to the
effect of conventional doxorubicin (19, 22).
Liposomes are non-toxic and biodegradable. This characteristics offer liposomes as a
cytotoxic drug and anticancer agent carrier directed to specific tumor site (20). It is crucial to
develop nanocarriers such as micelles and liposomes by means of cytotoxic agent carriers with
minimal detrimental effect on host cells and maximal drug encapsulation efficiency (20, 23).
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1.4. Types of nanocarriers
1.4.1. Polymeric micelles
Micelles are made up of one or two fatty acyl chains self-forming a hydrophobic corehydrophilic shell structure in an aqueous solution (24). The hydrophobic effect of polymeric
micelles allows for fatty acids to aggregate and prevent water molecules from internal core (24).
Polymeric micelles, an advanced form of copolymers, have two different chemical properties
(25). One is a hydrophobic blocks internal core and the other consists of a dense bush of poly
(ethylene oxide) (25). These features of polymeric micelles allow them to be used as a
hydrophobic drug carrier (25-28).
The size of polymeric micelles (10-150 nm) increases circulation time (27). The
hydrophilic shell can protect loaded drug and sequester and inhibit payload leakage (28). It is
also possible that polymeric micelles can be engineered by attaching of fatty acid side group to
enhance their encapsulation efficiency (28). Several formulations of micelles have been studied
in clinical trials (27). Polymeric micelles have been used to load paclitaxel which is one of the
cytotoxic drugs for cancer treatment with conjugation of cancer-specific peptide p160 using the
dialysis method (26).
However, there are numerous limiting effects with the use of polymeric micelles from
bench to clinic (28). Polymeric micelles as a drug carrier contain low drug encapsulation
efficiency, low permeability through the cell membrane, and poor circulation condition (25-28).
The engineered micelle shell and the improvement of micelle stability for spatial and temporal
drug delivery may be needed to not only overcome these obstacles but also to enhance the
therapeutic index of drug delivery carrier (27, 28).
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1.4.2. Liposomes
Liposomes have been utilized as drug and gene delivery agents for therapeutic and
medical application due to their non-immunogenic, and biodegradable characteristics (23).
Liposomes consist of amphipathic phospholipids self-forming into a lipid bilayer surrounding an
internal aqueous compartment (23, 29, 30). As shown in Fig 1.3, the hydrophobic core is
composed of two esterified fatty acyl chains which are aggregated to each other to form a lipid
bilayer (29). The assembled bilayer prevents the diffusion of water-soluble solute across the
membrane (24, 29). The head groups, hydrophilic portion of liposomes, strongly interact with
water molecules and face outward to form an internal aqueous compartment (24). This
characteristic of liposomes allows to carry hydrophilic and hydrophobic therapeutic material
such as drugs and genes (30-32). Water-soluble materials can reside in the aqueous core.
Liposomes can also contain water-insoluble and lipophilic drug inside the lipid bilayer (30).
Liposomes can encapsulate drug, gene and gas either separately or simultaneously (30).
The composition of phospholipids can determine both the degree of bilayer fluidity and
the physical properties of the liposomes (24). As depicted in Fig 1.4, Phosphatiylcholine (PC),
saturated fatty acids, are less fluid and reside in the exoplasmic face to provide membrane
curvature. The cylindrical shape of PC generates a flat monolayer. Phosphatidylethanolamine
(PE) contains long tails and a small head group that make corn-shaped lipids. These corn-shaped
PE are more fluid and form a curved bilayer. Cholesterol, one of major sterols in animals, plays
a key role in cellular membrane. Cholesterol restricts the random movement of long
phospholipid tails through an increase in thickness of the bilayer. The curvature of the bilayer is
influenced by the polar head groups and non-polar tails of its constituent phospholipids.
The physical properties of liposomes can provide therapeutic applications for targeted
delivery with reduced systemic toxicity and minimal premature degradation (33). Several
methods have been developed for liposomes to incorporate drug and gene. Liposomes have the
９

potential to carry small molecular weight drug and short DNA fragment for the treatment of
cardiovascular diseases and cancers (30, 32, 34). Tissue plasminogen activator (tPA)-loaded
liposomes were used as a targeted drug delivery agent for treatment of thrombolysis (30).
Doxorubicin and small molecular weight drugs can be encapsulated into liposomes for cancer
therapy (32). Plasmid DNA (pEGFP-N1) encapsulation in liposomes can increase the
encapsulation efficiency of DNA to interact with cells (35).

Figure 1.3 Structure of lipids in a bilayer membrane to form liposomes (36)
Permission to Use Granted by Elsevier
Liposomes self-forming into lipid bilayer are clearly separated into hydrophilic region and
hydrophobic region. Hydrophilic polar heads are attracted to the water and generate an aqueous
core of liposomes. Hydrophobic non-polar tails are directed to each other and form a lipid
bilayer.

１０

Figure 1.4 Effect of lipid composition on bilayer curvature (24)
Adapted from Lodish, H
The lipid structure of PC is made up of a large hydrophilic head and short hydrophobic tails.
However, PE is characterized by a small hydrophilic head and long hydrophobic tails. The
interaction between PC and PE generates membrane curved structure. A small hydrophilic head
of PE generates better incorporation with inner leaflet. Highly hydrophilic PE resides in
exoplasmic face and directs toward water molecule. The mixture of PE and PC forms lipid
bilayer.

1.5. Introduction of Echogenic liposomes
1.5.1. Ultrasound contrast agent (UCA)
Ultrasound contrast agent (UCA) refers to particles that reflect and scatter diagnostic
ultrasound waves (33). The use of UCA leads to the enhancement of ultrasound images by
increasing ultrasonic backscatter (37). The enhancement of backscatter intensity is one of the
most crucial factors for the increase of echogenicity for the detection of underlying physiological
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features (37, 38). Echogenicity is used for clinical diagnosis of cardiovascular diseases such as
thrombus (30, 39).
Echogenic liposomes (ELIP) are developed as a UCA for medical ultrasound imaging
and for non-invasive delivery of drugs and genes (33). Ultrasound reflectivity and stability of
ELIP can be determined by different lipid formulations and surfactants such as mannitol or BSA,
and with varying freezing conditions (40). ELIP formulations have been studied in a multiple
number of combinations of phospholipids and cholesterol.
Lipid components of ELIP consist of Egg phosphatidylcholine (EPC), dipalmitoyl-snglycero-3-phosphocholine

(DPPC),

dipalmitoyphoshati-dylethanolamine

(DPPE),

and

diapalmitoyl phosphate-dylglycerol (DPPG) with a molar ratio of 27: 42: 8: 8 (41). EPC is
unsaturated phospholipids and plays a role in making the lipid a phage region, although it
reduces echogenicity (40, 42). Three different saturated phospholipids such as DPPC, DPPG and
DPPE participate in the enhancement of ELIP reflectivity. DPPG is negatively charged and
facilitates bilayer hydration and prevents liposomes from aggregation (23). Only 8 mole % of
DPPG can be used due to toxicity of higher concentration of DPPG (42). Higher concentration
of DPPE affects the aggregation of phospholipids. Cholesterol, mostly hydrophobic among the
lipid composition, restricts the random movement of phospholipid by increasing the rigidity of
lipid bilayer (23, 24).
Mannitol is utilized as a surfactant in ELIP preparation due to its ability to generate
ultrasound reflectivity in freeze-thawing cycle (23). The role of mannitol is essential for the
disruption of the hydrophobic lipid bilayer which is exposed to air and incorporated with gas (23,
40). Concentration of 0.32 M mannitol can increase the size of liposomes and acoustic stability
(40). The optimal concentration of lipid compositions and mannitol solution is crucial for ELIP
to be utilized as a UCA to increase ELIP sensitivity to ultrasound application (30).
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1.5.2. Gas-containing echogenic liposomes (ELIP)
The amphipathic structure of ELIP provides a design to encapsulate gases allowing
direct gas delivery to target tissue (23). ELIP have been developed to contain a wide range of
bioactive gases such as argon, nitric oxide, xenon, hydrogen sulfide, and carbon dioxide by
elevated pressure with the gas of interest (30).
Several liposomal formulations to incorporate gas and hydrophilic drug into liposomes
have been developed by lyophilization and pressurization procedures. (30). Gas-containing ELIP
were prepared by the freezing-under-pressure method previously developed in our laboratory (23,
41). After drying and hydrating of the lipid film, liposomes undergo the gas injection process
using the elevated pressure-freeze method. Five milligrams of lipids can encapsulate 10 μl of gas
using relatively low pressure (23). As shown in Fig 1.5, gas entrapped into ELIP may reside in
hydrophobic surface by the difference of surface tension in the amphipathic lipids. Insoluble gas
forms a lipid monolayer-covered gas bubble in the aqueous compartment (33).
Gas-containing ELIP have been employed as a UCA for intravascular IVUS images (33).
The difference in density between entrapped gas and the lipid dispersion interface can create
ultrasound reflectivity and thus high contrast in IVUS images (30). Acoustically active gascontaining ELIP have potential to be visualized in IVUS images in real time (40).
Ultrasound can stimulate release of the payload of ELIP with the interaction with ELIP
(37). When gas entrapped into ELIP is exposed to ultrasound, they diffuse from the lipid shell by
the expansion of the gas bubbles and the oscillation effect on the liposome’s membrane (23, 30).
This acoustically active characteristic of gas-containing ELIP allows ultrasound-triggered
release of payload as well as ultrasound imaging (40).
The encapsulation of nitric oxide (NO) into ELIP, i.e. NO-ELIP, has the potential to
protect NO from being removed by NO scavengers as well as the possibility of liberating NO
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from NO-ELIP with ultrasound stimulation (41). The effect of NO-ELIP as a gas delivery carrier
has been studied for inhibition of intimal hyperplasia in cardiovascular disease treatment (41).
The use of NO-ELIP can provide a tool for a targeted bioactive gas delivery.

Figure 1.5 Structure of gas-containing ELIP with an internal aqueous phase and a gas bubble
between two monolayers (33).
Permission to Use Granted by Elsevier
Two different phages of ELIP allow to encapsulate water-soluble drug into the internal core
liposomes and water-insoluble drugs in the bilayer. ELIP can encapsulate gas between two
monolayers of lipid hydrophobic face.
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1.6. Physiological role of nitric oxide
1.6.1. Role of NO in cancer
Nitric oxide (NO) is a signaling molecule that regulates biological processes through
reactions by second messengers (43). The role of NO is highly complex in tumor biology (44).
NO has the potential to induce either cancer progression or cancer cell apoptosis depending on
intra-tumoral NO concentration (44, 45).
Recent studies have shown that high levels of NO leads to cytotoxic effects on cancer
cells by the reaction with O2- to generate the formation of peroxynitrite that acts as an apoptosis
inducer and toxic species during immune surveillance (46). High levels of NO also results in
DNA damage followed by the accumulation of p53 which is a major pro-apoptotic protein and
tumor suppressor. The accumulation of p53 meditates release of cytochrome C from
mitochondria, also known as intrinsic apoptosis (24).
On the other hand, low level of NO stimulates angiogenesis by the accumulation of
vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and plate-derived
growth factor (PDGF) (44). Cancer cells are able to proliferate the accumulation of VEGF (44,
47). Angiogenesis leads to tumor cell proliferation providing nutrients for growth and is a key
factor for tumor cells to metastasize (43).
A number of studies have been recently conducted to identify the use of NO as an oncopreventive agent for cancer treatment (47, 48). The role of NO in tumor biology is associated
with the properties and concentration of NO in the tumor microenvironment (44, 46).
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1.6.2. NO-induced pathway in breast cancer cells
The role of NO in tumor biology has been studied for more than 40 years, but the dual
function of NO for either pro-tumoral or anti-tumoral effect still remains unclear (48). An
increasing number of studies has demonstrated that there is a correlation between NO chemistry
and cytotoxicity in cancer (46).
The cell cycle, sequence of events for cell proliferation, consists of four phases shown in
Fig 1.6 (24). Cell growth is regulated by extracellular growth factor or hormonal signal, mitogen
growth factor during G1 phage. The restriction check point is located at G1 phage of the cell
cycle, which determines whether the cell grows enough to divide or postpone division or enter a
resting stage known as G0. The check point is mainly regulated by the cycline-dependent protein
kinase (CDK) inhibitor p16. p16 inhibits activity of cyclin complex, especially CDK 4 and
cyclin D1 (49). The down-regulation of cyclin D1 is essential for the inhibition of tumor cell
proliferation and tumor regression (49). It has been reported that NO-induced cytotoxicity in
cancer is associated with high levels (> 300 nM) of NO. A high levels of NO rapidly develops
cytostasis on cancer cells (44).
MDA-MB-231, a highly metastatic and undifferentiated human breast cancer cell,
undergoes NO-induced long lasting cytostasis in a high levels of NO (49). Cytostasis refers to a
halt in the cell cycle event that results from decreasing the translation of several cell cycle
proteins (24). Down-regulation of cyclin D1 prevents retinoblastoma protein (pRb) function
which controls the G1-S transition of the cell cycle depicted in Fig 1.6. Hypophosphorylation of
pRb induces an inactive E2F transcription factor followed by anti-progression of the cell cycle.
This inactive pRb is also known as a tumor suppressor (50).
It has been shown that NO in high concentration leads to MDA-MB-468 cell death
through the intrinsic activation with long-term exposure shown in Fig 1.7 (51, 52). The loss of a
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fully functional apoptotic program is regarded as the hallmark of all types of tumor cells (50).
The mitochondria are known to generate adenosine triphosphate (ATP) for cell respiration and
survival and make glucose metabolites (24). However, it has been shown that the mitrochondria
participates in apoptosis, known as intrinsic apoptotic pathway, which determines cell life or
death. The B-cell lymphoma 2 (BCL-2) protein consists of pro-apoptotic and anti-apoptoic BCL2 family based on regions of BCL-2 homology (51). The multidomain pro-apoptotic proteins in
the large family of BCL-2 family are subgrouped into Bax and Bak family that reside in the
outer membrane of mitrochondria (24). The activation of Bax and Bak, integral members of
intrinsic apoptosis, is correlated with the interaction between anti- and pro-apoptotic BCL-2
proteins. BH3-only proapoptotic proteins; BIM, BID and PUMA are major upstream regulators
of Bax and Bak activity (51). As apoptosis occurs, Bax and Bak trigger the release of
cytochrome c and a total collapse of the primary ATP-generating machinery (24). Cytochrome c
resides in the intermembrane space of mitochondria and acts as the primary biochemical
messenger in apoptotic process (49). After the initiation of apoptosis, the outer membrane of
mitochondria becomes depolarized and releases cytochrome c from the mitochondria surface
into the cytosol (24). Released cytochrome c activates caspase cascade that activates caspse-9
and other caspases. The levels of BCL-2 family proteins regulate whether cytochrome c is
located in the mitochondria or the cytosol.
There are two theories about the role of NO in the intrinsic activation (51). NO promotes
the activation of Bax and Bak which results in mitochondrial outer membrane permeabilization
(MOMP). This induces cytochrome c spilled out from the intermembrane space to the cytosol
followed by activating the caspase-dependent apoptotic signaling cascade (47, 51). Many studies
have confirmed that the combined loss of Bax, Bak and caspase-9 activity inhibits NO-induced
cell death in MDA-MB-468 cells (51, 52). NO-induced activation of intrinsic apoptotic pathway
induces programmed cell death in MDA-MB-468.
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Figure 1.6 NO-induced cytostasis in MDA-MB-231 (24)
Adapted from Lodish, H
MDA-MB-231 exposed to high concentration of NO is arrested at G1 phase of the cell cycle.
Cyclin D1 and CDK4 complex plays a key role to transition from G1 to S phase of the cell cycle.
NO-induced down- regulation of cyclin D1 inactivates pRb phosphorylation which activates
E2F1-3 transcription factor to generate cyclin/CDK complex for entering S phage of the cell
cycle. The down- regulation of cyclin D1 can induce NO-induced long lasting cytostasis.
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Figure 1.7 NO-induced apoptosis in MDA-MB-468 (24)
Adapted from Lodish, H
High levels of NO induce the intrinsic apoptotic pathway in MDA-MB-468 cell. NO activates
Bax and Bak proteins to release cytochrome C from mitochondria. Cytochrome C activates
caspase cascade followed by inducing cell apoptosis.
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CHAPTER 2
Specific Aim 1 - Development of NO-ELIP for Breast Cancer Treatment
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2.1. Materials and methodologies
2.1.1. NO-ELIP preparation by the freezing-under-pressure method
NO-ELIP was prepared by the previously developed freezing-under-pressure method
with the modification of lipid composition (41). All phospholipids and cholesterol were
purchased from Avanti Polar Lipids (Albaster, AL, USA). Echogenic liposomal dispersion
consists of Egg L-α-phosphatidylcholine (EPC); 1,2-dipamitoyl-sn-glycero-3-phosphocholine
(DPPC), L-α-dipalmitoylphosphatidyl-ethanolamine (DPPE), 1,2-diapalmitoyl-sn-glycero-3[phosphor-rac-l-glycerol]

(DPPG)

and

3β-[N-(N’,N’-dimethylaminoehane)-carbamoyl]

cholesterol hydrochloride (DC-Cholesterol·HCl) with a molar ratio of 27:42:8:8:15. The molar
percentage of saturated lipid was previously studied to increase the retention of echogenic
stability. The saturated phospholipid, DPPC is essential for the lipid formulation to increase
echogenicity. The stability of echogenicity of NO-ELIP was maximized at the amount of 42
mole % DPPC. The use of DC-Cholesterol·HCl, positively charged lipids, generates a cationic
polar head group of liposomes. The surface of positively charged liposomes improves the
interaction with negatively charged BCC membrane. The optimal concentration of cholesterol
was determined to be 15 mole % to maximize the acoustic stability of NO-ELIP and generate
substantial response with BCC.
Four phospholipids and cholesterol hydrochloride were dissolved in organic solvent
(chloroform and methanol at 9:1 ratio) to obtain lipid solution. The lipid solution underwent dry
process to form a thin lipid film using argon in a 50 °C H2O bath. Remaining organic solvent
was completely removed by high vacuum at ≤ 100 mTorr overnight. The lipid film was placed
under ultraviolet (UV) light for 15 minutes for sterilization. The hydration of the lipid film was
performed with deoxygenated 0.32 M mannitol. The final concentration of liposomal dispersion
was 10 mg/ml. Liposomal dispersion was sonicated for 5 minutes in a bath sonicator. The
sonicated liposomal dispersion was transferred into a 1.8 ml screw-cap borosilicate glass vial. It
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is essential to keep the hypoxic condition in solution to reduce NO reaction with oxygen. Nine
milliliters of NO washed and deoxygenated using the crystal form of sodium hydroxide (NaOH)
was injected into the glass vial through the use of a 12 ml syringe with a 0.5” needle applying
elevated pressure. Liposomal dispersion containing NO, known as NO-ELIP, was incubated for
30 minutes at room temperature. Pressurized liposomes were placed in -80 °C freezer for
overnight.

2.1.2. Measurement of echogenicity using intravascular ultrasound
Echogenicity of NO-ELIP was measured with the use of a 20-MHz high-frequency
intravascular ultrasound (IVUS) imaging catheter. NO-ELIP, resuspended in 5 ml of phosphate
buffered saline (PBS) in a 12×16 glass vial, was diluted to a concentration 0.1 mg/ml for IVUS
imaging. The catheter was inserted into the glass vial containing 50 µl of resuspended NO-ELIP
in 5 ml of PBS. The retention of ultrasound reflectivity of NO-ELIP was determined by
measuring the mean gray scale value (MGSV) in a region of interest (ROI) in the IVUS image.
MGSV of NO-ELIP resuspended in 10 mg/ml of BSA in PBS (PBS/BSA) was measured every
10 minutes until the first hour, and then once per hour up to 5 hours. Images of diluted NO-ELIP
were recorded in real time for subsequent playback and image analysis. Ultrasound images were
digitized with 8-bit (256 gray level) 640×480 pixel spatial resolution. As shown in Fig 2.1, the
region of interest was manually traced between the vial wall and the imaging catheter to
calculate MGSV of NO-ELIP excluding the area of the strut artifact of the IVUS images catheter.
MGSVs in the ROI were quantitated using Image-Pro Plus software (Version 4.1, Media
Cynernetics, Silver Spring, MD).
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Figure 2.1 IVUS image of a glass vial containing NO-ELIP
Outer ring indicates the glass vial containing 0.1 mg/ml of NO-ELIP. The black dot in the center
of the IVUS image represents the catheter. The red line between the glass vial wall and catheter
indicates ultrasound responsive liposomes. This area was set as an ROI. The brightness in the
ROI was quantitated as a MGSV.

２３

2.1.3. BCC lines and cell culture conditions
Two BCC lines, MDA-MB-231 and MDA-MB-468 from the America type culture
collection, (ATCC, VA, USA), were obtained from Dr. Sharina’s laboratory in the Division of
Cardiology at the University of Texas Health Science Center at Houston (UT-HSCH). These
BCC lines respond differently to high level of NO with the induction of different cellular
pathways. MDA-MB-231 is a highly undifferentiated BCC line with the absence of endogenous
NO production (49). This cell line was originally isolated from an aneuploid female with
mammary gland ductal carcinoma. On the other hand, MDA-MB-468 was isolated from a 51year-old female patient with metastatic adenocarcinoma of the breast and has relatively high
arginase activity which is a common substrate from L-Arginine (52).
The BCC lines were maintained with Dulbeccos’s modified Eagle Medium (DMEMHigh Glucose) supplemented with 10% fetal bovine serum (FBS), 5% penicillin streptomycin,
5% 100 mM sodium pyrurate, 5% MEM non-essential amino acids, 5% 1M HEPES at a
temperature of 37 °C in 0.5% of CO2.

2.1.4. Identification of BCC growth rate
It is important to determine the growth rate of BCCs to optimize breast cancer cell
culture conditions and estimate the cell cycle of each BCC line. The number of BCCs was
counted at different time points (0, 12, 24, and 48 hours) using a hemacytometer. The use of this
hemacytometer evaluates the number of cells per unit volume of a cell suspension by counting
cells under microscope. The instrument consists of a glass cover slip, counting chambers and a
sample introduction point. After the trypsinization of BCCs, uniform suspension of cells was
diluted to avoid overlapping of cells in the counting chamber. Ten microliters of cell suspension
was introduced at the edge of v-shape of the chamber per slide. The hemacytometer was placed
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on the microscope stage at 100 times magnification and cells above four 1 mm2 areas of the
counting chamber were counted. The total number of cells was calculated as follows.

2.1.5. Determination of BCC density
3-(4, 5-dimethylthiazol-2-yl)-2-5diphenyltetrazolium bromide (MTT) viability assay
was utilized for quantitative identification of cellular proliferation with response to growth factor
and cytokines. BCCs were plated into a 96 well plate with a final volume of 100 μl. Cell
suspension was diluted using 1:2 dilution in order to find optimal cell density for MTT assay.
Thiazoly blue tetrazolium bromide dissolved in PBS was prepared as a MTT solution. BCCs
were incubated with 10 μl of MTT solution (5 mg/ml in PBS) for 2 hours at 37 °C in 0.5 % of
CO2. The MTT solution was allowed to be metabolized and the cleavage of formazan dye
recorded by spectrophotometer. Resuspended formazan in 100 μl Dimethylsulfoxide (DMSO)
was utilized to read optical density at 580 nm using a SpectraMax® M5 spectrophotometer
(Molecular Devices, California, USA), to determine a correlation with cell quantity.
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2.2. Results
2.2.1. Stability of echogenicity of NO-ELIP
As depicted in Fig 2.2, MGSVs of NO-ELIP resuspended in PBS/BSA decreased over
time. NO-ELIP resuspended in PBS/BSA showed high echogenicity with MGSV of 174 ± 17 at
0 minute. While there was a stiff decrease of echogenicity until 60 minutes, the rate of
echogenicity reduced afterwards. MGSV of NO-ELIP with PBS/BSA reduced to 60 ± 2 in an
hour. NO-ELIP retained echogenicity with MGSV of 30 ± 12 at 5 hours.
NO-ELIP resuspended in PBS lost echogenicity over time as shown in Fig 2.3. There
was a rapid decrease of echogenicity in the first hour with MGSV of 13 ± 5 and the echogenicity
disappeared at 3 hours. The stability of NO-ELIP in PBS lasted for 3 hours.
Fig 2.4 shows the combined data of the echogenicity of NO-ELIP resuspended in PBS
and in PBS/BSA. There was a 40% enhancement of echogenicity of NO-ELIP in the presence of
PBS/BSA as compared to that in PBS at 1 hour (p < 0.01). Echogenicity of NO-ELIP
resuspended in PBS disappeared within 3 hours, yet that in BSA remained their echogenicity up
to 5 hours. Echogenicity of NO-ELIP resuspended in BSA/PBS was different from that in PBS
(p < 0.05).
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Figure 2.2 Echogenicity of NO-ELIP resuspended in PBS/BSA
The graph depicts the stability of NO-ELIP in PBS/BSA up to 5 hours. MGSVs of NO-ELIP
resuspended in PBS/BSA were measured up to 5 hours. NO-ELIP were diluted to 0.1 mg/ml in
10 mg/ml of BSA containing PBS.
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Figure 2.3 Echogenicity of NO-ELIP resuspended in PBS
The graph depicts the stability of NO-ELIP in PBS up to 5 hours. MGSV2 of NO-ELIP
resuspended in PBS was measured up to 5 hours using IVUS images. NO-ELIP were diluted to
0.1 mg/ml in PBS.
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Figure 2.4 Echogenicity of NO-ELIP resuspended in PBS/BSA and in PBS
The top line indicates MGSV of NO-ELIP resuspended in PBS/BSA. The bottom line represents
MGSV of NO-ELIP resuspended in PBS. Echogenicity of NO-ELIP suspended in PBS/BSA was
different from that in PBS (p < 0.05).
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2.2.2. Identification of growth rate and density of BCC
The growth rate and cell density of BCC were evaluated to optimize culture conditions.
As shown in Fig 2.5, the doubling time of MDA-MB-231 cells was found to be 24 hours in the
middle of the exponential growth phase. On the other hand, the number of MDA-MB-468 cell
became almost doubled after 36 hours as depicted in Fig 2.6. The growth rate of MDA-MB-468
was slower than that of MDA-MB-231.
As depicted in Fig 2.7, MDA-MB-231 cell concentration was measured by optical
density evaluated by the turbidity of cell suspension to estimate cell density. Optimal cell
densities of MDA-MB-231 cells were determined in the linear range of detection. Five hundred
thousands cells/ml of MDA-MB-231 were seeded in a 96 well plate at approximately 80 % of
cell confluency. As shown in Fig 2.8, optimal concentration of MDA-MB-468 cells was also 5 ×
105 cells/well in linear range of detection. These cell concentrations were used for subsequent
MTT assay studies.
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Figure 2.5 MDA-MB-231 growth curve
MDA-MB-231 cell growth rate was determined by counting the number of cells from 12 hours
up to 48 hours. Results are shown as mean and standard deviation of MDA-MB-231 cell
concentrations from four independent experiments.
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Figure 2.6 MDA-MB-468 growth curve
MDA-MB-468 cell growth rate was measured by counting the cell number from 12 hours to 48
hours. Results are expressed as the mean and standard deviation of MDA-MB-468 cell
concentrations from four different experiments.
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Figure 2.7 MDA-MB-231 cell densities
Various cell concentrations of MDA-MB-231 cell were seeded into 96 well plate to determine
optical density for MTT assay. Optical density increased as MDA-MB-231 cell concentration
increased. Red line indicates the optimal density (5 × 105 cells/ml) of MDA-MB-231 determined
in the linear range of detection for MTT assay.
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Figure 2.8 MDA-MB-468 cell densities
Various cell concentrations of MDA-MB-468 cell were seeded into 96 well plate to determine
optical density for MTT assay. Optical density increased as MDA-MB-468 cell concentration
increased. Red line indicates the optimal density (5 × 105 cells/ml) of MDA-MB-468 determined
in the linear range of detection for MTT assay.
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2.3. Discussion
The primary objective was to determine liposomal formulation of NO-ELIP for breast
cancer treatment. NO-ELIP was prepared by the freezing-under-pressure method as described.
The stability of NO-ELIP was evaluated by measuring of MGSVs in a region of interest in IVUS
images. The condition of breast cancer cell culture was optimized by measuring of growth rates
using hemacytometer and optimal cell densities using MTT viability assay.
The lipid formulation was previously identified as EPC: DPPC: DPPE: DPPG: DCcholesterol·HCl, with a molar ratio of 27:42: 8: 8: 15 (42). The use of 0.32 M mannitol
improved ultrasound reflectivity of NO-ELIP indicating that lipid fusion to incorporate gas of
interest occurred during the freezing process (30). The addition of DC-Cholesterol·HCl in NOELIP preparation generated positively charged NO-ELIP and preserved lipid bilayer structure.
The stability of NO-ELIP was evaluated by the measurement of echogenicity over time.
Previous studies in our laboratory have shown that NO gas entrapped in the lipid bilayer of ELIP
has the potential to generate ultrasound reflectivity and to be visualized in IVUS images (23, 30).
Fifty percent of NO resuspended in PBS/BSA was released from NO-ELIP in 1 hour and 24 %
of NO slowly diffused up to 5 hours. On the other hand, NO-ELIP resuspended in PBS released
50 % of NO in 20 minutes and 96 % of NO diffused out of NO-ELIP by 1 hour. The results
indicate that the use of BSA for resuspension of NO-ELIP can provide a more stable
environment. The surface of positively charged NO-ELIP interacted with the anionically charged
BSA molecule following the coating effect produced by BSA molecule on the surface of ELIP
(30). The BSA-coated NO-ELIP may prevent gas leakages and stiffen the lipid structure.
BCC doubling time is described by plotting a growth curve at various time points
throughout the growth cycle. Time-dependent BCC growth rate is crucial for the optimization of
BCC culture conditions in-vitro and the quantification of different treatment modalities (2).
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BCCs enter exponential growth during which the cell population doubles over a definable period
and characteristic for each BCC lines. MDA-MB-231 cell population became doubled at 24
hours allowing the cells to recover from trypsinization, construct their cytoskeleton and enable
them to re-enter the cell cycle. Population doubling of MDA-MB-468 was at approximately 36
hours. The determination of doubling time of BCCs provides the consistency of experimental
condition for BCC preparation.
Cell densities imply that the cells are attached and affect cell proliferation and
differentiation (6). At a high level of cell density, there is limited nutrient perfusion and limited
incidence of apoptosis in differentiated cells. On the other hand, low cell density is prone to
induce nutrient deprivation and induces the absence of cell contact signaling. It is crucial to
identify optimal cell density of BCC lines to conduct MTT assay. Optical density measurement
is important to convert into BCC viability in MTT assay. Therefore, a strong signal on optical
density within the linear range of detection is required to determine BCC viability. Five hundred
thousand cells per ml were determined as the optimal cell density for both BCC lines.
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CHAPTER 3
Specific Aim 2 – Efficiency of NO Delivery Strategy Using NO-ELIP
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3.1. Materials and methodologies
3.1.1. NO-donor treatment for BCC lines
MDA-MB-231 cells were seeded into a 96 well plate at a density of 5 × 105 cells/well in
100 μl. After 24 hours, the cells reached approximately 80% of cell confluent. They were serumstarved overnight and washed once with PBS. The stock solution of Spermine-NONOate was
1mM. A serial dilution using a dilution factor of 3 was performed with 0.1 M solution of NaOH.
Synchronized cells were exposed to 100 μl of the mixture of 4.1 μl of Spermine-NONOate and
410 μl of serum free medium, and placed at 37 °C and 0.5 % of CO2 for 24 hours.
MDA-MB-468 cells were plated into a 96 well plate at a density of 5 × 105 cells/well in
100 μl. After 36 hours, the cells were serum-starved overnight and washed once with PBS.
DETA-NONOate in 1 mM was diluted by a factor of 3. One hundred microliters of the mixture
of 4.1 μl of DETA-NONOate and 410 μl of serum free medium were treated to synchronize
MDA-MB-468 cells. The cells were exposed to DETA-NONOate for 24 hours at 37 °C and
0.5 % of CO2.
MTT viability assay was performed introducing 10 μl of MTT solution 5 mg/ml in PBS
into each well for 2 hours. One hundred microliters of solubilization solutions were added into
each well and incubated for an hour at 37 °C and 0.5 % of CO2. Purple formazan crystal was
completely solubilized, which allowed the quantitation of absorbance of purple formazan crystal
at 570 nm using SpectraMax® M5 spectrophotometer (Molecular Devices, CA, USA).
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3.1.2. NO-ELIP treatment for BCC lines
3.1.2.1. Effect of NO-ELIP on BCCs in PBS
Breast cancer cells, MDA-MB-231 cells and MDA-MB-468 cells were prepared in a 48
well plate at a density of 5 × 105 cells/well and allowed to grow depending on their growth rate.
After reaching 80 % of cell confluence, BCCs underwent serum starvation overnight and was
washed once with PBS. PBS underwent a degassing process using a vacuum machine followed
by the introduction of 30 ml of argon gas. Degassed PBS was sterilized using 0.45 µm of filter
(Millipore, Co Cork, Ireland). BCCs were treated with a serial dilution of NO-ELIP using a
dilution factor of 2 resuspended in degassed PBS. BCCs were exposure to 100 μl of NO-ELIP
with 400 µl of base medium at 37 °C and 0.5 % of CO2 for 5 hours. After 5 hours, BCCs were
washed twice with PBS. An MTT viability assay was performed. The yellow MTT solution was
made up of 5 mg of thiazoly blue tetrazolium bromide in 1 ml of PBS which allowed a final
concentration of 5 mg/ml. BCCs were incubated with 10 μl of MTT solution at 37 °C and 0.5 %
of CO2 for 2 hours. One hundred microliters of DMSO was introduced into each well. Optical
density was measured at 570 nm using SpectraMax® M5 spectrophotometer (Molecular Devices,
California, USA).

3.1.2.2. Effect of NO-ELIP on BCCs in BSA
BCCs were plated in a 48 well plate at a density of 5 × 105 cells/well and allowed to
grow depending on their growth rate. They underwent serum starvation overnight and were
washed once with PBS. Ten milligrams of BSA was added into 1 ml of degassed PBS which had
been filtered 0.45 µm for sterilization. NO-ELIP underwent serial dilutions of 1, 0.9, 0.5, 0.25,
and 0.125 mg/ml with filtered PBS/BSA. BCCs were treated with 100 µl of NO-ELIP and 400
µl of medium and placed in an incubator 37 °C and 0.5 % of CO2 for 5 hours. An MTT viability
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assay was performed after the treatment with NO-ELIP in order to determine BCC viability. The
yellow MTT solution was made up of 5 mg of thiazoly blue tetrazolium bromide in 1 ml of PBS.
BCCs were incubated with 10 μl of MTT solution at 37 °C and 0.5 % of CO2 for 2 hours. One
hundred microliters of DMSO was introduced into each well and optical density was measured
at 570 nm using SpectraMax® M5 spectrophotometer (Molecular Devices, CA, USA).

3.1.3. Data analysis
Optical density obtained from the MTT assay was transformed to a percentage of cell
viability with respect to a control with no treatment. The lowest measured value of cell viability,
as a baseline response, was subtracted from all other data. The highest measured value was
regarded as 100% allowing all data to be normalized to the 100% scale.
Dose response curves were determined by nonlinear regression curve fitting using the
equation of  

100
with the slope factor. This method can provide regression and
1  10(   log IC 50 )

outlier removal. A sigmoidal dose response curve was generated that follows Gaussian or normal
distribution function (Graphpad Prism 3.0, GraphPad Software Inc, CA, USA).
IC

50,

known as a half-maximal inhibitory concentration, is the concentration of a

cytotoxic agent to induce approximately 50 % decrease of cell viability (53). IC50 is also defined
as the concentration to generate a half way response between the baseline and maximal response
(53). The IC50 values of the NO-donors were obtained in logarithmic scale as a log IC50. The
anti-logarithm of IC50 is required to convert to the concentration of NO-donors. For example,
NO-donor concentration were 1, 3, 10, 30, 100, 300, 1,000, 3,000, and 10,000 μM and converted
to logarithmic scale; 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0. However, it was not necessary
to transform the concentrations of NO-ELIP to logarithmic scale due to the short range order in
concentration.
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3.2. Results
3.2.1. NO-dose dependent MDA-MB-231 cell viability by spermine-NONOate treatment
Dose response curves for MDA-MB-231 cell viability with spermine-NONOate
treatment are depicted in Fig 3.1. Each point is presented with mean ± standard deviation for 14
samples. IC50 values ranged from 0 to 4 log μM of Spermine-NONOate (corresponds from 1 to
10,000 μM). Spermine-NONOate with concentration ranged from 0 to 2 μM in a logarithmic
scale (corresponds from 1 to 30 μM) showed little cytotoxicity on MDA-MB-231 cell viability.
The IC50 value in MDA-MB-231 was 2.82 μM in a logarithmic scale (corresponds to 656 μM).
This result indicates that MDA-MB-231 responded to Spermine-NONOate in a dose-dependent
manner and approximately 50% inhibition of MDA-MB-231 cell viability was induced from 656
μM spermine-NONOate.
3.2.2. NO-dose dependent MDA-MB-468 cell viability by DETA-NONOate treatment
The cytotoxic effect of DETA-NONOate on MDA-MB-468 cell viability was examined
as illustrated in Fig 3.2. Data shown are as mean ± standard deviation with 14 samples. DETANONOate with concentration ranged from 0.47 to 2 μM in a logarithmic scale (corresponds from
3 to 100 μM) had little effect on MDA-MB-468 cell death. The IC50 value of DETA-NONOate
was 2.59 μM on a logarithmic scale (which is equal to 397 μM). DETA-NONOate in 397 μM
concentration induced 50% inhibition of MDA-MB-468 cell viability. Higher concentration of
DETA-NONOate over the IC50 potentiated to induce maximal cytotoxicity on MDA-MB-468
cell viability.

４１

Figure 3.1 MDA-MB-231 cell viability with Spermine-NONOate
MDA-MB-231 cell viability was determined by MTT assay. Data are shown as mean ± standard
deviation from fourteen independent experiments. The dose response curve was obtained. IC50
value of Spermine-NONOate was 656 ± 3.02 μM.

４２

Figure 3.2 MDA-MB-468 cell viability with DETA-NONOate
MDA-MB-468 cell viability was determined by MTT assay. Results are shown as mean ±
standard deviation from fourteen independent experiments. The dose-response curve was
obtained. IC50 value of DETA-NONOate was 397 ±3.98 μM.
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3.2.3. Dose dependent BCC response to NO-ELIP resuspended in PBS
To confirm NO-induced cell death and lipid effect on BCCs, NO-saturated mannitol and
empty ELIP were treated to BCCs. As shown in Fig 3.3, only 1 % MDA-MB-231 cells were
alive with NO-saturated mannitol. On the other hand, 85 % MDA-MB-231 cells remained viable
with 1 mg/ml of empty ELIP. Sixteen percent of MDA-MB-468 cells were alive with NOsaturated mannitol as depicted in Fig 3.4. There was 77 % MDA-MB-468 viability after treated
with 1 mg/ml of empty ELIP. The results represent that NO-induced cytotoxicity is not from
lipid toxicity but mainly due to the NO-saturated mannitol.
NO-ELIP induced concentration-dependent cytotoxic effect on MDA-MB-231 is
depicted in Fig 3.5. NO-ELIP in concentrations of 0.125 and 0.25 mg/ml generated little
cytotoxicity on MDA-MB-231. The NO-ELIP concentration of 0.7 mg/ml was determined to be
the cytotoxic IC50 at which MDA-MB-231 cell growth was inhibited to around 50 %. There was
only 1 % of MDA-MB-231 cells remained alive with 1 and 2 mg/ml of NO-ELIP. The
concentration of NO-ELIP over 1 mg /ml was effective to induce maximum cytotoxic activity on
MDA-MB-231 cells. This result indicates that MDA-MB-231 cells respond to NO-ELIP
depending on concentration, and 0.7 mg/ml of NO-ELIP is the critical concentration to inhibit
50% of MDA-MB-231 cell growth.
The concentration response curve on MDA-MB-468 is shown in Fig 3.6. NO-ELIP in
concentrations of 0.125 and 0.25 mg/ml induced in high MDA-MB-468 cell viability. The
cytotoxic IC50 value of NO-ELIP inhibiting MDA-MB-468 cell growth by approximately 50 %
was 0.47 mg/ml. The concentration of NO-ELIP over 0.7 mg/ml can effectively induce MDAMB-468 cell death. The data indicates a dose-dependent relationship between NO-ELIP
concentration and MDA-MB-468 cell response. NO-ELIP in concentration of 0.47 mg/ml has
potential to be used as the critical concentration of NO-ELIP to induce approximately 50 % of
MDA-MB-468 cell death.
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Figure 3.3 MDA-MB-231 cell viability with NO-saturated mannitol and empty ELIP
MDA-MB-231 cell viability was determined by MTT assay. Data are shown as mean ± standard
deviation from nine different experiments. These results demonstrated a difference between the
two groups (p< 0.001).
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Figure 3.4 MDA-MB-468 cell viability with NO-saturated mannitol and empty ELIP
MDA-MB-468 cell viability was determined by MTT assay. Data are shown as mean ± standard
deviation from three different experiments. These results demonstrated a difference between the
two groups (p< 0.001).
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Figure 3.5 MDA-MB-231 cell viability with NO-ELIP in PBS
MDA-MB-231 cell viability was determined by MTT assay. Data are shown as mean ± standard
deviation of MDA-MB-231 cell viability from ten independent experiments. The dose-response
curve was generated. IC50 value of NO-ELIP in PBS was 0.70 ± 0.35 mg/ml.
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Figure 3.6 MDA-MB-468 cell viability with NO-ELIP in PBS
MDA-MB-468 cell viability was determined by MTT assay. Data are shown as mean ± standard
deviation of MDA-MB-468 cell viability from twelve independent experiments. The doseresponse curve was obtained. IC50 value of NO-ELIP in PBS was 0.47 ± 0.03 mg/ml.
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3.2.4. Dose dependent BCC response to NO-ELIP resuspended in PBS/BSA
The effect of NO-ELIP resuspended in PBS/BSA on MDA-MB-231 cell viability is
shown in Fig 3.7. At the concentration of 0.125 and 0.25 mg/ml of NO-ELIP resuspended in
PBS/BSA, 60 % of MDA-MB-231 cells remained alive. The cytotoxic IC50 value of NO-ELIP
was 0.5 mg/ml. MDA-MB-231 cell viability dramatically decreased with the concentration of
0.5 mg/ml. The data indicate that MDA-MB-231 cells respond to NO-ELIP concentration
resuspended in PBS/BSA in a dose-dependent manner, and 0.5 mg/ml of NO-ELIP is the critical
concentration to inhibit 50% MDA-MB-231 cell growth.
The dose response curve of MDA-MB-468 is shown in Fig 3.8. NO-ELIP in
concentrations of 0.125 and 0.25 mg/ml reduced 80% of MDA-MB468 cell viability. NO-ELIP
concentration of 0.41 mg/ml was determined as the cytotoxic IC50. However, 20% of MDA-MB468 cells were viable with 1 mg/ml of NO-ELIP treatment. The data indicate that MDA-MB-468
cells respond to NO-ELIP in a dose-dependent manner.
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Figure 3.7 MDA-MB-231 cell viability with NO-ELIP resuspended in PBS/BSA
MTT assay was performed to determine MDA-MB-231 cell viability. Data are shown as mean ±
standard deviation of MDA-MB-231 cell viability from ten different experiments. The doseresponse curve was generated. IC50 value of NO-ELIP in PBS was 0.51 ± 1.02 mg/ml.

５０

Figure 3.8 MDA-MB-468 cell viability with NO-ELIP resuspended in PBS/BSA
MTT assay was performed to identify MDA-MB-468 cell viability. Data are shown as mean ±
standard deviation of MDA-MB-468 cell viability from four independent experiments. The doseresponse curve was obtained. IC50 value of NO-ELIP in PBS was 0.41 ± 0.18 mg/ml.
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3.3. Discussion
The data demonstrates that high levels of NO entrapped in NO-ELIP can induce
cytotoxic effects on MDA-MB-231 and MDA-MB-468 after 5 hours of treatment. The specific
aim of the study was to determine the efficiency of NO delivery strategy using NO-ELIP. The
efficiency of NO delivery of two NO-donors such as spermine-NONOate and DETA-NONOate
were compared with that of NO-ELIP. A MTT viability assay was conducted after the treatments
with NO-donors and NO-ELIP to identify BCC viability.
The half life of Spermine-NONOate is 39 minutes at 37 °C (52). Approximately 50% of
MDA-MB-231 cells underwent apoptosis with 656 μM of Spermine-NONOate in response to
spontaneous NO release from Spermine-NONOate. The cytotoxic effects of approximately 50%
of MDA-MB-468 cell death was produced by DETA-NONOate at 397 μM of concentration due
to steady-state NO release with 20 hours of half-life at 37 °C (45). The concentration of NOdonors over the cytotoxic IC50 potentiated to effectively induce BCC death. There was a dosedependent relationship between the concentration of NO generated by NO-donors and BCC
viability.
NO-ELIP, the NO delivery carrier used in this study, induced a cytotoxic effect on
BCCs in a dose-dependent manner. The improvement of NO-ELIP stability generated by the
coating effect of BSA was determined by the comparison with NO-ELIP in the absence of BSA
on BCC response. There was 28.6 % decrease in the cytotoxic IC50 value of NO-ELIP in the
presence of BSA on MDA-MB-231 cell viability. MDA-MB-468 cells responded to NO-ELIP
resuspended in BSA with 12.8 % decrease in its cytotoxic IC50 concentration. These results
indicate that BCCs are more sensitive to NO-ELIP resuspended with PBS/BSA. It can be
assumed that MDA-MB-231 are more sensitive than MDA-MB-468 in regard to cell death.
However, higher concentrations of the cytotoxic IC50 are required for MDA-MB-231 due to its
highly metastatic characteristic.
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The use of NO-ELIP was effective to regulate the amount of NO delivered to BCCs and
in prohibiting NO from being scavenged by hemoglobin in the systemic circulation (41).
Decrease of NO exposure time during systemic delivery is crucial to reduce reaction with
oxygen followed by the formation of nitrite (NO2). NO2 induces cytotoxicity in non-malignant
cells and in the microenvironment (41). This study demonstrated that NO can be packaged using
NO-ELIP and delivered to BCCs for NO-induced cytotoxic effect. The cytotoxic IC50 value of
NO-ELIP may provide a therapeutic index of NO-ELIP for breast cancer treatment.
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CHAPTER 4
Specific Aim 3 - Enhancement of NO Release with Ultrasound Application
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4.1. Materials and Methodologies
4.1.1. Ultrasound-triggered NO release from NO-ELIP
An ultrasound-triggered NO release study was performed with the experimental setup as
shown in Fig 4.1 (40). The setup was made up of a transwell insert allowing to hold NO-ELIP
solution inside the transwell (30). Eight hundred microliter of NO-ELIP was introduced inside
the transwell. The bottom of the transwell insert was made up of 0.4 μm pore polyester
membrane. The transwell insert was placed on an acoustic absorber to eliminate acoustic
reflectivity (23). A layer of water was placed between the transwell insert and the acoustic
absorber to remove the air interference and avoid ultrasound reflection. Sonitron 1000 (Rich Mar
Inc, TN, USA) was utilized with ultrasound parameters of 1 MHz, 1 W/cm2 intensity and 100%
duty cycle for 10 seconds of duration using a probe size with 1.2 cm diameter. Ten minutes after
thawing the NO-ELIP, they were exposed to mechanical ultrasound. Right after the ultrasound
was applied, echogenicity was measured using IVUS imaging for 5 hours.

Figure 4.1 Experimental setup for ultrasound-triggered release study (40)

Adapted from Huang, S. L.
Resuspended NO-ELIP were introduced into the transwell insert. The use of the acoustic
absorber and water layer allowed to remove the air interference and avoid ultrasound reflectivity.
Ultrasound was applied and echogenicity of N-ELIP was measured.
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4.1.2. Measurement of echogenicity of NO-ELIP
NO-ELIP were reconstituted to a lipid concentration of 0.1 mg/ml. The release of NO
from NO-ELIP was measured using IVUS imaging at 0, 10, 20, 30, 60, 120, 180, 240, and 300
minutes. Fifty microliters of NO-ELIP collected from the transwell after ultrasound application
put in 5 ml of PBS/BSA in a 12×16 glass vial at room temperature (21 to 22 °C). The IVUS
imaging catheter was inserted into the glass vial containing reconstituted NO-ELIP. IVUS
imaging was performed at different time points with fixed instrumental setting such as gain,
zoom, and reject. At each time point, an IVUS image of reconstituted NO-ELIP was recorded in
real time. The regions of interest in the recorded images were manually traced between the vial
wall and the imaging catheter to calculate MGSV (23). MGSV was computed using the ImageHistogram function in Image-Pro Plus software (Version 4.1, Media Cynernetics, Silver Spring,
MD). Background MGSV of PBS/BSA was determined as the lower limit of the measurement.
The MGSV measurement of NO-ELIP were reduced by the background value of MGSV (23). In
order to identify ultrasound-triggered NO release from NO-ELIP, the percentage retention of
MGSV was calculated using the initial MGSV of each sample regarded as 100%. The MGSV of
each time point was divided by the initial MGSV and multiplied by 100. Therefore, MGSVs of
NO-ELIP were normalized to percentage retention. The percentage retention of MGSV of six
samples were averaged.
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4.2. Results
4.2.1. Ultrasound-triggered NO release from NO-ELIP
Ultrasound application improved NO release from NO-ELIP compared to spontaneous
NO release. Comparison of the percentage retention of echogenicity of NO-ELIP with (■) and
without (□) ultrasound application is depicted in Fig. 4.2. The top line indicates the percentage
retention of echogenicity of NO-ELIP without ultrasound application. The bottom line represents
the percentage retention of echogenicity of NO-ELIP with ultrasound application. Ultrasound
application performed 10 minutes after the reconstitution of NO-ELIP caused significant
increase in NO release from NO-ELIP. Ultrasound application enhanced NO release at 10
minute as depicted in Fig 4.3. The black bar indicates the MGSV of NO-ELIP without
ultrasound application. The gray bar represents the MGSV of NO-ELIP with ultrasound
application. NO-ELIP without ultrasound application showed higher echogenicity with a MGSV
of 116 ± 18. However, MGSV of NO-ELIP with ultrasound application was reduced to 71 ± 16.
There was an average of 26% increase in NO release from NO-ELIP with ultrasound application.
Although NO-ELIP were exposed to ultrasound only one time, the loss of echogenicity
with ultrasound application was significantly increased (p< 0.05). The echogenicity of NO-ELIP
with ultrasound application dramatically decreased and almost disappeared at 2 hours. However,
the decrease in NO-ELIP echogenicity without ultrasound application was steady up to 5 hours.
The results demonstrate that there was ultrasound-triggered release of NO from NO-ELIP,
indicating ultrasound application can improve NO release from NO-ELIP.
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Figure 4.2 Percent retention of echogenicity of NO-ELIP with and
without ultrasound application
This graph illustrates percentage of retention of echogenicity at different time points. Red arrow
indicates the time point of ultrasound application 10 minutes after NO-ELIP reconstitution. This
ultrasound-triggered NO release study was carried out with the use of ultrasound parameters of 1
MHz, 1 W/cm2 and 100% duty cycle for 10 seconds of duration. After ultrasound application,
echogenicity of NO-ELIP was measured by IVUS imaging. The top line indicates percentage
retention of NO-ELIP without ultrasound application. The bottom line represents the percentage
retention of NO-ELIP with ultrasound application. Results are represented as mean ± standard
deviation from six independent experiments. These results showed significant difference (p<
0.05).
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Figure 4.3 MGSV of NO-ELIP with and without ultrasound
application
This bar graph clearly represents the comparison of MGSV at the 10 minutes time point with and
without ultrasound application. Black bar indicates the MGSV of NO-ELIP without ultrasound
application. Gray bar represents the MGSV of NO-ELIP applied ultrasound at 10 minutes.
Results are shown as mean ± standard deviation from six independent experiments. These results
showed a significant difference (p< 0.001).
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4.3. Discussion
The principal objective of this chapter was to investigate ultrasound-triggered NO
release from NO-ELIP and to evaluate the enhancement of NO release efficiency with
ultrasound stimulation. The hypothesis is that ultrasound can enhance NO release from NOELIP.
Ultrasound was applied to thawed NO-ELIP 10 minutes after thawing process with
ultrasound parameters of 1 MHz, 1 W/cm2, and 100 % duty cycle for 10 seconds of duration
time. NO release from NO-ELIP was quantitated by measuring echogenicity in IVUS images.
Decrease of echogenicity of NO-ELIP after ultrasound application indicates increase of NO
amount liberated from NO-ELIP stimulated by ultrasound application. The rapid decrease in
NO-ELIP echogenicity was observed at 10 minutes. Echogenicity of NO-ELIP disappeared 2
hours after ultrasound application. The results indicate that ultrasound application induces an
average of 26 % enhancement of NO release from NO-ELIP.
Ultrasound-triggered gas diffusion is determined by liposomal composition, the
encapsulated gas properties, and ultrasound parameters (30). It was hypothesized that ultrasound
can induce oscillation behavior of liposomes and force NO diffused from NO-ELIP at a low
acoustic power. Ultrasound-controlled NO release has the potential to be utilized for targeted
monotherapy of breast tumor treatment (54).
Ongoing research has demonstrated ultrasound-induced release of air and other inert
gases from ELIP (33). To investigate the mechanism of NO release from NO-ELIP using
ultrasound application, direct measurement of the NO amount diffused out of NO-ELIP must be
evaluated in future research. The most crucial ultrasound characteristics are correlated with
power input and duration of Sonication effects (37). Ultrasound parameters need to be optimized
to maximize the NO release profile from NO-ELIP.
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CHAPTER 5
Summary and Future Directions
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5.1. Summary
NO-ELIP have the potential not only to encapsulate and deliver NO to BCCs, but also to
control NO release via direct ultrasound exposure. The present study includes a number of invitro studies to demonstrate the efficiency of NO-ELIP as NO gas delivery agent for BCC
treatment. First, the stability of NO-ELIP over time was investigated with the measurement of
echogenicity using ultrasound imaging. Secondly, NO dose-dependent response of BCCs with
two known NO donors were determined and compared to those with NO-ELIP. Lastly,
ultrasound-controlled NO release from NO-ELIP was evaluated by ultrasound application
utilizing the measurement of echogenicity.
As described in Chapter 2, the echogenicity of NO-ELIP resuspended in PBS/BSA was
more stable than that of NO-ELIP in PBS up to 5 hours. This result may provide important
information as to design experiments of NO-ELIP treatment for BCCs. BCCs were exposed to
NO-ELIP for 5 hours in order for NO-ELIP to generate a cytotoxic effect on BCCs viability.
The utility of NO-donors verified the NO dose-dependent characteristics of the BCCs.
The effect of NO-ELIP on BCC death was highly dependent on concentration compared with
that of NO-donors in Chapter 3. In order to demonstrate NO-induced cell death, NO-saturated
mannitol solution and empty ELIP were used to investigate NO-induced cytotoxicity on BCCs.
This study revealed that NO-induced cytotoxicity was not by lipid effect, but mainly by NO.
Chapter 4 shows that NO-ELIP were able to liberate encapsulated NO triggered by
ultrasound application. There was an average of 26 % enhancement of NO release from NOELIP after applying ultrasound. Ultrasound application induces a rapid NO release rate from
NO-ELIP.
In this study, a unique cytotoxic gas delivery system using NO-ELIP has been developed
for breast cancer treatment. NO-ELIP can encapsulate NO gas more stably with the
improvement of purified NO gas injection. The use of BSA enhances NO-ELIP stability and
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induces a stable rate of NO release. Cytotoxic efficacy of NO released from NO-ELIP on BCC
viability was determined and compared with NO-donor treatments for the BCCs. Ultrasound
application over NO-ELIP can enhance the rate of NO release.

5.2. Future directions
Previous research demonstrated that stead-state release of NO is more effective for
generating programmed tumor cell death (49). The spontaneous NO release from NO-ELIP, in
an initially rapid and then later slower pattern, may limit the cytotoxic effect of NO-ELIP on
BCC viability. The enhancement of prolonged NO release from NO-ELIP is needed for further
investigation with modification of lipid shell composition. The use of 50 mole % of DPPG may
enhance the echogenicity and the toxic effect of NO-ELIP. Positively charged NO-ELIP with
further optimized DC-Cholesterol·HCl mole % may improve the interaction between NO-ELIP
and BCCs and enhance the efficacy of NO delivery to BCCs.
It has been shown that the presence of mannitol in the freezing step is essential for the
preparation of gas-containing liposomes (40). The freezing mannitol solution generates lipid
fusion followed by the formation of a gas bubble in the lipid bilayer. The use of mannitol not
only improves encapsulation efficiency of gas but also enhances echogenicity (23). However, the
use of mannitol was less effective for increasing permeability through the BCC membrane.
Other carbohydrates and surfactants may be utilized to enhance the permeability of NO-ELIP to
BCC. Moreover, NO-ELIP conjugated to specific biomarkers of BCCs such as Her-2, ER, PR,
and EGFR may increase the permeability of NO-ELIP through the BCC membrane and provide
targeted NO gas delivery.
In the present study, NO release from NO-ELIP was indirectly quantitated using IVUS
images. We assumed that loss of echogenicity from NO-ELIP would correspond to NO release
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from NO-ELIP due to ultrasound responsive characteristic of NO and NO-ELIP. The amount of
NO encapsulated into NO-ELIP needs to be directly measured by a chemiluminescence
technique to identify the therapeutic index of detrimental NO concentration for breast cancer
treatment.
Ultrasound parameters need to be optimized for an improved NO release profile from
NO-ELIP and improved efficacy of NO-ELIP as ultrasound contrast agent. Ultrasound-triggered
spatial and temporal NO releases needs to be evaluated through in-vivo experiments for targeted
monotherapy of breast tumor treatment. The application of clinical Doppler ultrasound may
improve the therapeutic effect of NO-ELIP as a toxic agent delivery carrier. In order to improve
ultrasound effect on the mechanism of NO release, the sensitivity of NO-ELIP to ultrasound may
be enhanced with modification of lipid formulation. BCC response to ultrasound-driven NO
release needs to be studied to verify the enhancement of NO-ELIP on therapeutic application.
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Appendices

Figure A.1. IVUS images of NO-ELIP resuspended in PBS/BSA

Figure A.2. IVUS images of NO-ELIP resuspended in PBS
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